VANCOUVER, BRITISH COLUMBIA, December 6, 2018 | Chinook Tyee Industry Limited (“Chinook“) (TSXV: XCX) announces, that at the annual general and special meeting held on December 5, 2018, Chinook shareholders approved a three-for-one share split (the “Share Split“), previously announced on November 16, 2018, of Chinook’s Class A voting common shares (the “Common Shares“). Chinook currently has 3,405,932 Common Shares issued and outstanding and, upon completion of the Share Split, Chinook expects to have 10,217,796 fully diluted common shares outstanding. The record date for the Share Split will be December 14, 2018, and the Common Shares will trade on an ex-split basis at the opening of the market on December 13, 2018. The Share Split is subject to final approval of the TSX Venture Exchange (the “TSXV“).
Computershare Investor Services Inc. will be directed to effect the Share Split on or around the record date without any action on the part of the holders of the Common Shares.
Chinook Tyee Industry Limited is a holding company, listed in Canada on the TSXV, with two European subsidiaries, AMP Alternative Medical Products GmbH and Mercury Partners & Company plc.
About AMP Alternative Medical Products
AMP Alternative Medical Products GmbH is a German biopharmaceutical company focused on providing cannabis formulations and dose delivery systems for German patients, with offices in Erfurt and Berlin Germany. For further information, visit www.amp-eu.com, Twitter or Instagram.
ON BEHALF OF THE BOARD OF DIRECTORS
“Mr. Alex Blodgett”
Neither the TSXV nor its Regulation Service Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
This news release contains certain forward-looking statements, including statements regarding the proposed Share Split and the timing thereof. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements, oral or written, made by itself or on its behalf, except as required by applicable law.
For further information, please contact: Alex Blodgett
Tel: +1 (236) 833-1602